By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Better Testing for ALS with This Health Startup
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Innovations > Better Testing for ALS with This Health Startup
BusinessMedical Innovations

Better Testing for ALS with This Health Startup

Deanna Pogorelc
Deanna Pogorelc
Share
4 Min Read
SHARE

ALS treatmentOriginally published on MedCityNews.com. It might not seem like a fitting name for a medical company – or at least one that you’d expect – but Iron Horse Diagnostics actually makes a lot of sense.

ALS treatmentOriginally published on MedCityNews.com. It might not seem like a fitting name for a medical company – or at least one that you’d expect – but Iron Horse Diagnostics actually makes a lot of sense.

The name comes from baseball great Lou Gehrig, nicknamed “The Iron Horse.” He died from amyotrophic lateral sclerosis (ALS), one of the neurodegenerative diseases the startup thinks it can help diagnose earlier.

The one-man, Scottsdale, Arizona company is developing a series of protein-based biomarkers to function as diagnostic and prognostic tests for the disease, which affects nerve cells in the brain and the spinal cord. Because ALS has non-specific symptoms that could also be indicative of other diseases, it’s difficult to diagnose.

More Read

Report: Avoidable ‘Never Events’ Increase in Minnesota Hospitals
Healthcare Data Breaches Up 32%
The Evolution of Medical Imaging and Its Impact on the Healthcare System
Don’t Like the Sound of ACOs? Here’s an Alternative
End-to-End ICD-10 Testing: Are You Prepared?

There’s also no cure for ALS, but Robert Bowser, professor and chairman of neurobiology at Barrow Neurological Institute, said the interventions available to help manage the disease tend to work better if they’re administered sooner. One FDA approved drug, riluzole (Sanofi-Aventis), for example, has been shown to slow progression of the disease in clinical studies. Typically, the disease is fatal within five years of diagnosis.

Bowser is also founder of Iron Horse Diagnostics, and he said that the company has just secured a pharmaceutical partner to validate its two ALS tests. “We’ve already performed studies in 23 centers in the U.S. where samples were collected and shipped to the lab,” he said. “The overall accuracy of the test was 93 percent.”

Next, he’s gearing up to run another 300-subject prospective study at six more sites. The lab-based tests look for levels of proteins called pNfH and complement c3, which Bowser and fellow researchers have identified as being important components of the disease. One test uses a patient’s cerebrospinal fluid, and the other uses a blood sample, he said.

Down the line, he hopes to develop additional prognostic assays that would be used to monitor ALS progression and gauge the effectiveness of new drugs in clinical trials. In the meantime, Iron Horse is also working on a blood biomarker that would allow earlier and more confident diagnosis of traumatic brain injury.

Before launching Iron Horse in 2012 with technology he developed as a faculty member at the University of Pittsburgh, Bowser co-founded a drug development company called Knopp Biosciences. That Pittsburgh-based company is developing drugs for ALS and in 2010 signed a licensing deal with Biogen Idec. Earlier this year, though, the drug failed to prolong life or slow loss of muscular function in people with the disease in a Phase 3 trial.

Supported so far by an SBIR grant from the National Institutes of health and some private funding, Iron Horse is seeking funding for clinical trials.

TAGGED:ALSLou Gehrig's disease
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

a woman walking on the hallway
6 Easy Healthcare Ways to Sit Less and Move More Every Day
Health
September 9, 2025
Clinical Expertise
Healthcare at a Crossroads: Why Leadership Matters More Than Ever
Global Healthcare
September 9, 2025
travel nurse in north carolina
Balancing Speed and Scope: Choosing the Nursing Degree That Fits Your Goals
Nursing
September 1, 2025
intimacy
How to Keep Intimacy Comfortable as You Age
Relationship and Lifestyle Senior Care
September 1, 2025

You Might also Like

cigna
BusinessHealth ReformMedical EthicsNewsPolicy & Law

Cigna’s Decision on Genetic Testing Exposes Educational Gaps in Today’s Healthcare

August 21, 2013

Coronary Stents Show Clinical and Economic Staying Power

April 18, 2011
10-year, Health Care Reserve Fund Enacted
BusinessHospital AdministrationMedical InnovationsNewsTechnology

3 Ways that Crowdfunding Can Benefit the Healthcare Market

April 12, 2012

Is Technology a Cost Driver or a Cost Saver in Health Care?

June 12, 2011
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?